NVGN 2.50 Novogen Ltd $NVGN Hit a 52 week low of 2.50 Closing the day 10:22 at 2.50 -0.16 -6.02% With a day low of 2.50 and a total volume of 13,100.
NVGN Recent Posts: http://investorshangout.com/Novogen-Limited-NVGN-54935/
NVGN Novogen Ltd Recent Headline News
ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer
PR Newswire - Mon Sep 29, 8:00AM CDT
Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) CEO & Chairman, Dr Graham Kelly, conducted an interview with ABC TV that was broadcast on Saturday September 27th during the national 7.00 pm news bulletin and on the following day on Weekend Breakfast. The interview concerned the Company's efforts in bringing its drug candidate, Trilexium, into the clinic in Australia for the treatment of primary brain cancers such as glioblastoma multiforme.
NVGN: 2.57 (-0.09)
Graham Kelly PhD, CEO & Chairman attended the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 29, 7:00AM CDT
Novogen Ltd. (ASX: NRT, NASDAQ: NVGN)
NVGN: 2.57 (-0.09)
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference
PR Newswire - Wed Sep 03, 6:49PM CDT
Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10th in New York. Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology. His presentation will take place at the New York Palace Hotel and will begin at 10:25am.
NVGN: 2.57 (-0.09)
Novogen Announces Results of General Meeting of Shareholders
PR Newswire - Wed Aug 13, 7:00AM CDT
Australia-US biotechnology company, Novogen Ltd. (ASX: NRT, NASDAQ: NVGN), an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 12 in Sydney, Australia. A total of 28.3M shares were represented in person or by proxy at the meeting, during which the following resolutions were passed (95% in favor):
NVGN: 2.57 (-0.09)
Novogen awarded funding in support of Muscular Dystrophy research studies using super-benzopyran compounds
M2 - Wed Aug 13, 5:18AM CDT
Biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) said on Tuesday that it has received funding from the FSHD Global Research Foundation to find effective treatments for a range of musculo-degenerative diseases, including facioscapulohumeral dystrophy (FSHD), a form of muscular dystrophy and genetic skeletal muscle hereditary disease.
NVGN: 2.57 (-0.09), NRT: 16.58 (-0.04)
Novogen Receives Funding Support To Commence Studies In Muscular Dystrophy
PR Newswire - Tue Aug 12, 7:13AM CDT
The Australian biotechnology company, Novogen Limited (ASX: NRT; NASDAQ: NVGN), today announced receipt of funding from the FSHD Global Research Foundation as part of the Company's efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).
NVGN: 2.57 (-0.09)
Novogen And CanTx Appoint Contract Manufacturers To Produce Clinical Batches Of Cantrixil(TM)
PR Newswire - Fri Jul 25, 6:00AM CDT
Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd. (ASX; NRT: NASDAQ; NVGN), today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil(TM). CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound into the clinic by mid- 2015.
NVGN: 2.57 (-0.09)
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells
PR Newswire - Tue Jun 17, 6:00AM CDT
Australian oncology drug development company Novogen Limited [ASX:NRT; NASDAQ:NVGN] and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the potency seen in animal models to date, and the potential to prevent recurrence, Novogen and CanTx believe that Intra-Peritoneal Trx-1 could be utilized as a first-line therapy for ovarian cancer.
NVGN: 2.57 (-0.09)
Novogen and CanTx's experimental drug Trx-1 passes important test to fight abdominal cancers
M2 - Wed Mar 19, 7:56AM CDT
Australian biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) revealed on Tuesday that its lead candidate drug, Trx-1, has demonstrated a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells in partnership with CanTx.
NVGN: 2.57 (-0.09), NRT: 16.58 (-0.04)
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo
PR Newswire - Tue Mar 18, 7:00AM CDT
Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells.
NVGN: 2.57 (-0.09)
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
PR Newswire - Wed Mar 12, 10:00AM CDT
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly's presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City.
NVGN: 2.57 (-0.09)
Novogen Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Mon Mar 10, 12:27PM CDT
Novogen Limited (ASX: 'NRT'; NASDAQ: 'NVGN'
, an oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.
NVGN: 2.57 (-0.09)
Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence
PR Newswire - Tue Mar 04, 5:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board of directors as non-executive directors. David W. Gryska, an industry expert with over 20 years of experience in management at many of the top U.S. biotechnology companies, will serve as a strategic advisor to the board with a focus on U.S. capital markets and as a U.S. shareholder liaison.
NVGN: 2.57 (-0.09)
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
CHLN: 0.93 (unch), CHTP: 6.52 (-0.03), TCX: 16.74 (+0.39), NVGN: 2.57 (-0.09), SHOS: 14.33 (+0.08), MERU: 3.86 (-0.01)
Direct Energy Revenue Up 28% in 2013
PR Newswire - Thu Feb 20, 1:15AM CST
Direct Energy, North America's largest competitive energy and energy-related services company, today announced gross revenue for the full year 2013 of US $11.4 billion (£7.3 billion), an increase of 28 percent, and an operating profit of US$436 million (£276 million). Direct Energy is the North American subsidiary of Centrica plc (LSE: CNA). Centrica reported full year 2013 revenues of US$41.6 billion (£26.6 billion) with an operating profit of US$4.2 billion (£2.7 billion).
HLF: 37.60 (-0.25), PFE: 30.32 (-0.10), GNC: 43.63 (-0.03), NVGN: 2.57 (-0.09), INFI: 14.22 (-0.03)
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
PR Newswire - Fri Dec 20, 7:00AM CST
Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).
NVGN: 2.57 (-0.09)
Market Maker Surveillance Report. CKSW, NVGN, USU, NDLS, DQ, RNDY, Losing Stocks With Lowest Price Friction For Monday, July 8th 2013
M2 - Tue Jul 09, 4:23AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3901 companies with "abnormal" market making, 2937 companies with positive Friction Factors and 2297 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Clicksoftware Technologies Ltd (NASDAQ:CKSW), Novogen Ltd (NASDAQ:NVGN), USEC Inc (NYSE:USU), NATIONAL DLR STORES (NASDAQ:NDLS), Daqo New Energy Corp (NYSE
Q), Roundy's Inc (NYSE:RNDY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks
DQ: 32.61 (+0.08), CKSW: 7.36 (-0.04), USU: 0.83 (-0.24), NDLS: 23.30 (-0.17), NVGN: 2.57 (-0.09), RNDY: 3.49 (+0.08)
Market Maker Surveillance Report. NURO, NVGN, ET, LOTE, INFI, BEAT, Winning Stocks With Lowest Price Friction For Tuesday, June 4th 2013
M2 - Wed Jun 05, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3819 companies with "abnormal" market making, 2025 companies with positive Friction Factors and 3252 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NeuroMetrix Inc (NASDAQ:NURO), Novogen Ltd (NASDAQ:NVGN), E*TRADE FINL CORP (NYSE:ET), LORIMAR TELEPICTURES (OTC:LOTE), Infinity Pharmaceuticals Inc (NASDAQ:INFI), CardioNet Inc (NASDAQ:BEAT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NURO: 1.61 (-0.06), BEAT: 8.18 (+0.01), NVGN: 2.57 (-0.09), INFI: 14.22 (-0.03)
NVGN, AVEO, QQEW, Removed From Naked Short Lists Today
M2 - Mon May 20, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
AVEO: 0.96 (unch), NVGN: 2.57 (-0.09), QQEW: 41.90 (+0.06)
NVGN, ABIO, RVXCF, QQEW, Added To Naked Short Lists Today
M2 - Thu May 09, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), ARCA Biopharma Inc (NASDAQ:ABIO), RESVERLOGIX CORP (OTC:RVXCF), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
ABIO: 0.87 (-0.07), NVGN: 2.57 (-0.09), QQEW: 41.90 (+0.06)
NVGN Recent Posts: http://investorshangout.com/Novogen-Limited-NVGN-54935/
NVGN Novogen Ltd Recent Headline News
ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer
PR Newswire - Mon Sep 29, 8:00AM CDT
Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) CEO & Chairman, Dr Graham Kelly, conducted an interview with ABC TV that was broadcast on Saturday September 27th during the national 7.00 pm news bulletin and on the following day on Weekend Breakfast. The interview concerned the Company's efforts in bringing its drug candidate, Trilexium, into the clinic in Australia for the treatment of primary brain cancers such as glioblastoma multiforme.
NVGN: 2.57 (-0.09)
Graham Kelly PhD, CEO & Chairman attended the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 29, 7:00AM CDT
Novogen Ltd. (ASX: NRT, NASDAQ: NVGN)
NVGN: 2.57 (-0.09)
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference
PR Newswire - Wed Sep 03, 6:49PM CDT
Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10th in New York. Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology. His presentation will take place at the New York Palace Hotel and will begin at 10:25am.
NVGN: 2.57 (-0.09)
Novogen Announces Results of General Meeting of Shareholders
PR Newswire - Wed Aug 13, 7:00AM CDT
Australia-US biotechnology company, Novogen Ltd. (ASX: NRT, NASDAQ: NVGN), an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 12 in Sydney, Australia. A total of 28.3M shares were represented in person or by proxy at the meeting, during which the following resolutions were passed (95% in favor):
NVGN: 2.57 (-0.09)
Novogen awarded funding in support of Muscular Dystrophy research studies using super-benzopyran compounds
M2 - Wed Aug 13, 5:18AM CDT
Biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) said on Tuesday that it has received funding from the FSHD Global Research Foundation to find effective treatments for a range of musculo-degenerative diseases, including facioscapulohumeral dystrophy (FSHD), a form of muscular dystrophy and genetic skeletal muscle hereditary disease.
NVGN: 2.57 (-0.09), NRT: 16.58 (-0.04)
Novogen Receives Funding Support To Commence Studies In Muscular Dystrophy
PR Newswire - Tue Aug 12, 7:13AM CDT
The Australian biotechnology company, Novogen Limited (ASX: NRT; NASDAQ: NVGN), today announced receipt of funding from the FSHD Global Research Foundation as part of the Company's efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).
NVGN: 2.57 (-0.09)
Novogen And CanTx Appoint Contract Manufacturers To Produce Clinical Batches Of Cantrixil(TM)
PR Newswire - Fri Jul 25, 6:00AM CDT
Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd. (ASX; NRT: NASDAQ; NVGN), today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil(TM). CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound into the clinic by mid- 2015.
NVGN: 2.57 (-0.09)
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells
PR Newswire - Tue Jun 17, 6:00AM CDT
Australian oncology drug development company Novogen Limited [ASX:NRT; NASDAQ:NVGN] and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the potency seen in animal models to date, and the potential to prevent recurrence, Novogen and CanTx believe that Intra-Peritoneal Trx-1 could be utilized as a first-line therapy for ovarian cancer.
NVGN: 2.57 (-0.09)
Novogen and CanTx's experimental drug Trx-1 passes important test to fight abdominal cancers
M2 - Wed Mar 19, 7:56AM CDT
Australian biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) revealed on Tuesday that its lead candidate drug, Trx-1, has demonstrated a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells in partnership with CanTx.
NVGN: 2.57 (-0.09), NRT: 16.58 (-0.04)
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo
PR Newswire - Tue Mar 18, 7:00AM CDT
Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells.
NVGN: 2.57 (-0.09)
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
PR Newswire - Wed Mar 12, 10:00AM CDT
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly's presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City.
NVGN: 2.57 (-0.09)
Novogen Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Mon Mar 10, 12:27PM CDT
Novogen Limited (ASX: 'NRT'; NASDAQ: 'NVGN'
, an oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. NVGN: 2.57 (-0.09)
Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence
PR Newswire - Tue Mar 04, 5:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board of directors as non-executive directors. David W. Gryska, an industry expert with over 20 years of experience in management at many of the top U.S. biotechnology companies, will serve as a strategic advisor to the board with a focus on U.S. capital markets and as a U.S. shareholder liaison.
NVGN: 2.57 (-0.09)
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
CHLN: 0.93 (unch), CHTP: 6.52 (-0.03), TCX: 16.74 (+0.39), NVGN: 2.57 (-0.09), SHOS: 14.33 (+0.08), MERU: 3.86 (-0.01)
Direct Energy Revenue Up 28% in 2013
PR Newswire - Thu Feb 20, 1:15AM CST
Direct Energy, North America's largest competitive energy and energy-related services company, today announced gross revenue for the full year 2013 of US $11.4 billion (£7.3 billion), an increase of 28 percent, and an operating profit of US$436 million (£276 million). Direct Energy is the North American subsidiary of Centrica plc (LSE: CNA). Centrica reported full year 2013 revenues of US$41.6 billion (£26.6 billion) with an operating profit of US$4.2 billion (£2.7 billion).
HLF: 37.60 (-0.25), PFE: 30.32 (-0.10), GNC: 43.63 (-0.03), NVGN: 2.57 (-0.09), INFI: 14.22 (-0.03)
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
PR Newswire - Fri Dec 20, 7:00AM CST
Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).
NVGN: 2.57 (-0.09)
Market Maker Surveillance Report. CKSW, NVGN, USU, NDLS, DQ, RNDY, Losing Stocks With Lowest Price Friction For Monday, July 8th 2013
M2 - Tue Jul 09, 4:23AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3901 companies with "abnormal" market making, 2937 companies with positive Friction Factors and 2297 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Clicksoftware Technologies Ltd (NASDAQ:CKSW), Novogen Ltd (NASDAQ:NVGN), USEC Inc (NYSE:USU), NATIONAL DLR STORES (NASDAQ:NDLS), Daqo New Energy Corp (NYSE
Q), Roundy's Inc (NYSE:RNDY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks DQ: 32.61 (+0.08), CKSW: 7.36 (-0.04), USU: 0.83 (-0.24), NDLS: 23.30 (-0.17), NVGN: 2.57 (-0.09), RNDY: 3.49 (+0.08)
Market Maker Surveillance Report. NURO, NVGN, ET, LOTE, INFI, BEAT, Winning Stocks With Lowest Price Friction For Tuesday, June 4th 2013
M2 - Wed Jun 05, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3819 companies with "abnormal" market making, 2025 companies with positive Friction Factors and 3252 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NeuroMetrix Inc (NASDAQ:NURO), Novogen Ltd (NASDAQ:NVGN), E*TRADE FINL CORP (NYSE:ET), LORIMAR TELEPICTURES (OTC:LOTE), Infinity Pharmaceuticals Inc (NASDAQ:INFI), CardioNet Inc (NASDAQ:BEAT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NURO: 1.61 (-0.06), BEAT: 8.18 (+0.01), NVGN: 2.57 (-0.09), INFI: 14.22 (-0.03)
NVGN, AVEO, QQEW, Removed From Naked Short Lists Today
M2 - Mon May 20, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
AVEO: 0.96 (unch), NVGN: 2.57 (-0.09), QQEW: 41.90 (+0.06)
NVGN, ABIO, RVXCF, QQEW, Added To Naked Short Lists Today
M2 - Thu May 09, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), ARCA Biopharma Inc (NASDAQ:ABIO), RESVERLOGIX CORP (OTC:RVXCF), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
ABIO: 0.87 (-0.07), NVGN: 2.57 (-0.09), QQEW: 41.90 (+0.06)
